

# POZEN<sup>®</sup>

INC.

The Pharmaceutical Development Company

1414 Raleigh Road, Suite 400  
Chapel Hill, North Carolina 27517  
Main: 919-913-1030  
www.pozen.com

## *Treximet<sup>®</sup>* *Next Generation Migraine Therapy*

*Treximet<sup>®</sup>* is the brand name for the combination of sumatriptan 85 mg as the succinate salt, formulated with RT Technology™, and naproxen sodium 500 mg, in a single tablet, for the acute treatment of migraine in adults. RT Technology, currently only available in *Imitrex* Tablets, is an innovative tablet formulation designed to rapidly disintegrate and disperse in the stomach after swallowing, which may allow the medicine to be absorbed more quickly in the blood stream.

### About Migraine:

Migraine affects more than 28 million people in the United States alone, of which roughly three out of four migraine sufferers are women. According to the International Headache Society's diagnostic criteria, migraine is characterized by recurrent headaches lasting 4 to 72 hours (untreated) and with symptoms including moderate to severe headache pain, throbbing head pain, head pain located on one side of the head, head pain aggravated by routine activity, nausea, vomiting, and sensitivity to light and sound. Migraine can be disabling and sufferers may miss days of work, lose time with family and friends, and be unable to pursue basic daily activities.

The combination therapy was developed in collaboration with GlaxoSmithKline (GSK) and is the first triptan-based product with multiple mechanisms of action. Recent data suggest that the pathophysiology of migraine is complex and that migraine is not merely a vascular problem, but a result of a chain of events that are both vascular and neurological. These events develop early in the migraine process, often long before a patient actually feels the sensation of headache pain. The expected benefits of *Treximet* over triptan monotherapy

## *Treximet<sup>®</sup>* The Next Generation Migraine Treatment

# Treximet™



Courtesy of GSK

include: faster onset of pain relief, longer duration of action, effective in more patients, similar tolerance to triptan monotherapy with a superior benefit/risk profile.

### Collaboration with GlaxoSmithKline

In June 2003, POZEN licensed to GSK the exclusive rights in the United States to commercialize proprietary combinations of GSK's triptans with a long-acting NSAID for the acute treatment of migraine. The deal terms include \$80 million in upfront and certain development and regulatory milestone payments and an additional \$80 million in sales performance milestones based on achievement of certain sales thresholds. Additionally, POZEN will receive royalties based on net sales. GSK, POZEN's partner, will commercialize *Treximet*. It is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan and an Anti-inflammatory pain reliever in a single tablet.